 |
This study is ongoing, but not recruiting patients.
Satraplatin is an orally administered platinum compound currently under investigation for the treatment of
patients with advanced hormone-refractory prostate
cancer (HRPC) that has failed prior chemotherapy.
| • |
Satraplatin is an investigational drug |
|
